FIGURE 1 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
Year: 2023
Type: other
Abstract: OS by KRAS and treatment arm. A, OS in non-variant patients by radiation level; B, OS in non-variant patients by cetuximab; C, OS in KRAS-variant patients by radiation level; D, OS within KRAS-variant patients by cetuximab. Radiation level P values stratified by cetuximab; cetuximab P values stratified by radiation level.
Authors: Joanne B. Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A. Masters, George R. Blumenschein, Joe Y. Chang, Bo Lu, Adam P. Dicker, Jeffrey A. Bogart, Yolanda I. Garces, Samir Narayan, Clifford G. Robinson, Vivek S. Kavadi, Joel S. Greenberger, Christopher D. Koprowski, James Welsh, Elizabeth M. Gore, Robert M. MacRae, Rebecca Paulus, Jeffrey D. Bradley
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4387540907